COMMUNIQUÉS West-GlobeNewswire

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
07/07/2025
Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform Accelerating the [...]
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
07/07/2025
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain [...]
Collegium Announces $150 Million Share Repurchase Program
07/07/2025
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical [...]
JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025
07/07/2025
IRVINE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the New York Valves 2025 [...]
Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025
07/07/2025
MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire’s [...]
Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call
07/07/2025
MARKHAM, Ontario, July 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2025 after market [...]
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
07/07/2025
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
07/07/2025
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
07/07/2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 [...]
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
07/07/2025
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with Sarborg Limited [...]
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
07/07/2025
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
07/07/2025
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months [...]
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
07/07/2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development
07/07/2025
Innovative System Combines Physical and Virtual Chemistry with Discovery-Focused AI and Robotic Automation to Find Better Molecules Faster and Less Expensively MENLO PARK, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- [...]
Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services
07/07/2025
PASADENA, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Nudj Health, the leading AI-powered lifestyle medicine services company, is proud to announce the appointment of Dr. Padmaja Patel as Chief Medical Officer of [...]
First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy
07/07/2025
PARIS, July 07, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to [...]
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
07/07/2025
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16 [...]
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
07/07/2025
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today [...]
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
07/07/2025
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ( [...]

Pages